Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.

被引：0
|
作者：
Smit, WM
Sufliarsky, J
Spanik, S
Wagnerová, M
Kaye, S
Oza, AM
Gore, M
Williams, K
Johri, A
Huinink, WWT
机构：
[1] Med Spectrum Twente, Enschede, Netherlands
[2] Natl Canc Inst, Bratislava, Slovakia
[3] St Elisabeth Canc Inst, Bratislava, Slovakia
[4] Inst Oncol, Kosice, Slovakia
[5] Royal Marsden Hosp, Sutton, Surrey, England
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Novartis Pharmaceut AG, Basel, Switzerland
[8] Novartis Pharmaceut Corp, E Hanover, NJ USA
[9] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：468S / 468S
页数：1
相关论文
共 50 条
  • [1] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer
    Smit, W. M.
    Sufliarsky, J.
    Spanik, S.
    Wagnerova, M.
    Kaye, S.
    Oza, A. M.
    Gore, M.
    Williams, K. J.
    Johri, A.
    Huinink, W. W. ten Bokkel
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 262
  • [2] Phase I/II dose-escalation trial of patupilone administered every 3 weeks (q 3 wk) in patients (pts) with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer
    Smit, Willem M.
    Honkoop, Aafke H.
    Spanik, Stanistav
    Wagnerova, Maria
    Sufliarsky, Jozef
    Oza, Amit M.
    Kaye, Stan
    Pereno, Raffaele
    Sklenar, Ivo
    Huinink, W. W. ten B.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 127 - 127
  • [3] A phase I/II dose-escalation trial of EP0906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer.
    Smit, WM
    Honkoop, AH
    Spanik, S
    Wagnerova, M
    Huinink, WWTB
    Oza, AM
    Kaye, SB
    Mull, R
    Pereno, R
    Sklenar, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 474S - 474S
  • [4] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer
    Sanchez, J. M.
    Osterlind, K.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Sklenar, I.
    John, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 327
  • [5] Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer.
    Osterlind, K
    Sánchez, JM
    Zatloukal, P
    Hamm, J
    Belani, CP
    Kim, E
    Felip, E
    Johri, A
    Berton, M
    Sklenar, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 647S - 647S
  • [6] A phase I/II dose-escalation trial of patupilone (EPO906) administered every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Oesterlind, Kell
    Sanchez, Jose
    Zatloukal, Petr
    Perry, Michael
    Hamm, John
    Belani, Chandra
    Kim, Edward
    Vansteenkiste, Johan
    Felip, Enriqueta
    Berton, Myriam
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 167 - 167
  • [7] Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma
    Lokhorst, Henk M.
    Plesner, Torben
    Gimsing, Peter
    Nahi, Hareth
    Minnema, Monique
    Lassen, Ulrik Niels
    Krejcik, Jakub
    Laubach, Jacob
    Lisby, Steen
    Basse, Linda
    Richardson, Paul Gerard Guy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Wendtner, C. M.
    Mahadevan, D.
    Coutre, S.
    Hillmen, P.
    Stilgenbauer, S.
    Frankfurt, O.
    Bloor, A.
    Bosch, F.
    Furman, R.
    Uharek, L.
    Kimby, E.
    Gobbi, M.
    Dreisback, L.
    Hurd, D.
    Sekeres, M.
    Gribben, J.
    Shah, S.
    Parseval, L. Moutouh-de
    Chanan-Khan, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 371 - 372
  • [9] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
    Richardson, Paul G.
    Weller, Edie
    Jagannath, Sundar
    Avigan, David E.
    Alsina, Melissa
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    McKenney, Mary
    Delaney, Carol
    Mitsiades, Constantine S.
    Hideshima, Teru
    Dalton, William
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5713 - 5719
  • [10] Phase I/II trial of patupilone once every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Osterlind, K
    Sánchez, J
    Zatloukai, P
    Hamm, J
    Belani, C
    Kim, E
    Felip, E
    Sklenar, I
    Berton, M
    Johri, A
    [J]. LUNG CANCER, 2005, 49 : S261 - S261
12345